Cogstate News

The latest from Cogstate, leaders in optimizing the measurement of cognition

Cogstate Expands Executive Team, Appointing Ken Billard as Chief Commercial Officer

November 19, 2019

New Haven, CT – November 19, 2019: The neuroscience technology company, Cogstate Ltd (ASX.CGS), announced today that Ken Billard has joined the company in the role of Chief Commercial Officer. Ken brings proven expertise in sales leadership and strategic partnering to Cogstate, where he will oversee the global sales organization to develop and execute strategies […]

Cogstate Strengthens Executive Team with Appointment of Chief Technology Officer

March 15, 2017

New Haven, CT – March 15, 2017: The cognitive science company, Cogstate Ltd (ASX.CGS) announced today that Richard Gleeson has joined the senior leadership team as Chief Technology Officer, strengthening the company’s ability to deliver transformative innovations to optimize the measurement of cognition in clinical trials and healthcare. Reporting directly to Cogstate Chief Operating Officer, […]

Cogstate Announces Appointment of Jane McAloon to Board of Directors

January 30, 2017

Cogstate Ltd (ASX.CGS) is pleased to announce the appointment of Jane McAloonas an Independent Non-Executive Director and, following release of the Appendix 4D Half Year Financial Report on 23 February 2017, Chair of the Audit & Compliance Committee of Cogstate Ltd. Until mid-2015, Jane was part of the Group Management Committee of BHP Billiton as […]

Cogstate Announces Appointment of Dr. Richard Mohs to Board of Directors

January 24, 2017

Cogstate Ltd (ASX.CGS) is pleased to announce the appointment of Dr. Richard Mohs as a non-executive director. Dr. Mohs retired from Eli Lilly in 2015, where he held several leadership positions including Vice President for Neuroscience Early Clinical Development and Leader of the Global Alzheimer’s Drug Development Team. Before joining Eli Lilly in 2002, Richard […]